Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants

Abstract excerpt

The emergence of numerous variants of SARS-CoV-2, the causative agent of COVID-19, has presented new challenges to the global efforts to control the COVID-19 pandemic. Here, we obtain two cross-neutralizing antibodies (7D6 and 6D6) that target Sarbecoviruses' receptor-binding domain (RBD) with sub-picomolar affinities and potently neutralize authentic SARS-CoV-2. Crystal structures show that both antibodies bind...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Bacillus and Francisella bacterial research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to SARS-CoV-2 and COVID-19 Research